Hjem › Plateepitelcancer i hode og hals › Georgia › Atlanta
Kliniske studier for Plateepitelcancer i hode og hals i Atlanta, GA
24 studier for Plateepitelcancer i hode og hals søker deltakere på steder i og rundt Atlanta (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekruttererFase 1
- Emory University, Atlanta
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
RekruttererFase 3
- Emory University, Atlanta
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RekruttererFase 2
- Emory University Hospital Midtown, Atlanta
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
RekruttererFase 3
- Emory University Hospital Midtown, Atlanta
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
RekruttererFase 1
- Emory University, Atlanta
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
RekruttererFase 2
- Emory Proton Therapy Center, Atlanta
- Emory University Hospital Midtown, Atlanta
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RekruttererFase 2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
RekruttererObservasjonsstudie
- Morehouse, Atlanta
- Piedmont Healthcare, Atlanta
- Winship Cancer Institute, Emory University, Atlanta
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RekruttererFase 2
- Emory University School of Medicine, Atlanta
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
RekruttererFase 2/3
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RekruttererFase 1/2
- Winship Cancer Institute - Emory University, Atlanta
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
RekruttererFase 1/2
- Emory University, Atlanta
Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Rekrutterer
- Emory Midtown University Hospital/Winship Cancer Institute, Atlanta
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RekruttererFase 1/2
- Winship Cancer Institute, Emory University, Atlanta
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
RekruttererFase 3
- GSK Investigational Site, Atlanta
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
RekruttererFase 2
- USA10-0, Atlanta
Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial
Rekrutterer
- Emory University Hospital, Atlanta
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
RekruttererFase 3
- Emory University, Atlanta
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
RekruttererFase 1/2
- Research Site 111, Atlanta
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
RekruttererFase 1
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
RekruttererFase 2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RekruttererFase 1/2
- Research Site 114, Atlanta
- Research Site 139, Atlanta
Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer
RekruttererTidlig fase 1
- Emory University Hospital Midtown, Atlanta
A Beta-only IL-2 ImmunoTherapY Study
RekruttererFase 1/2
- Emory - Winship Cancer Institute, Atlanta
Plateepitelcancer i hode og hals-studier i andre byer
- Houston, TX47 studier
- Los Angeles, CA42 studier
- Boston, MA40 studier
- New York City, NY39 studier
- Nashville, TN39 studier
- St. Louis, MO28 studier
- Arlington, VA26 studier
- Philadelphia, PA26 studier
- Chicago, IL26 studier
- San Antonio, TX22 studier
- New Haven, CT22 studier
- Pittsburgh, PA22 studier
Andre studier i Atlanta
- Kreft (alle typer)49 studier
- Ikke-småcellet lungekreft47 studier
- Multipelt myelom42 studier
- Brystkreft41 studier
- Prostatakreft33 studier
- Akut myelogen leukemi31 studier
- Eggstokkreft29 studier
- Kolorektal kreft29 studier
- Lungekreft29 studier
- Metastatisk kreft28 studier
- Major depresjon25 studier
- Hjertesvikt25 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.